BR112017010490A2 - roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. - Google Patents
roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.Info
- Publication number
- BR112017010490A2 BR112017010490A2 BR112017010490A BR112017010490A BR112017010490A2 BR 112017010490 A2 BR112017010490 A2 BR 112017010490A2 BR 112017010490 A BR112017010490 A BR 112017010490A BR 112017010490 A BR112017010490 A BR 112017010490A BR 112017010490 A2 BR112017010490 A2 BR 112017010490A2
- Authority
- BR
- Brazil
- Prior art keywords
- rodent
- evaluate
- human cells
- human
- drug directed
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 241000283984 Rodentia Species 0.000 title 6
- 239000003814 drug Substances 0.000 title 2
- 229940079593 drug Drugs 0.000 title 2
- 210000005260 human cell Anatomy 0.000 title 2
- 210000004027 cell Anatomy 0.000 title 1
- 210000001161 mammalian embryo Anatomy 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 241001529936 Murinae Species 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Abstract
são fornecidos animais não humanos, métodos e composições para produção e uso dos mesmos, em que os referidos animais não humanos compreendem uma humanização do gene de um cluster de diferenciação (cd) endógeno, em particular, uma humanização de um gene de cd47. os referidos animais não humanos podem ser descritos, em algumas modalidades, como tendo uma modificação genética em um gene de cd47 endógeno de modo que os referidos animais não humanos expressem um polipeptídeo cd47 que inclua uma porção humana e uma porção não humana (por exemplo, uma porção murina).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462087992P | 2014-12-05 | 2014-12-05 | |
PCT/US2015/062614 WO2016089692A1 (en) | 2014-12-05 | 2015-11-25 | Non-human animals having a humanized cluster of differentiation 47 gene |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017010490A2 true BR112017010490A2 (pt) | 2018-04-03 |
Family
ID=54979926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017010490A BR112017010490A2 (pt) | 2014-12-05 | 2015-11-25 | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
Country Status (29)
Country | Link |
---|---|
US (4) | US20160345549A1 (pt) |
EP (4) | EP3086637B1 (pt) |
JP (2) | JP6730277B2 (pt) |
KR (3) | KR102313073B1 (pt) |
CN (2) | CN107205368B (pt) |
AR (1) | AR102888A1 (pt) |
AU (2) | AU2015355328B2 (pt) |
BR (1) | BR112017010490A2 (pt) |
CA (1) | CA2967834C (pt) |
CY (2) | CY1121547T1 (pt) |
DK (3) | DK3466255T3 (pt) |
ES (2) | ES2870462T3 (pt) |
FI (1) | FI3850946T3 (pt) |
HK (1) | HK1225912A1 (pt) |
HR (3) | HRP20231707T1 (pt) |
HU (2) | HUE043132T2 (pt) |
IL (2) | IL286403B2 (pt) |
LT (3) | LT3466255T (pt) |
MX (1) | MX2017007293A (pt) |
NZ (1) | NZ731471A (pt) |
PL (3) | PL3466255T3 (pt) |
PT (3) | PT3850946T (pt) |
RS (3) | RS61774B1 (pt) |
RU (1) | RU2728412C2 (pt) |
SG (2) | SG10202103050YA (pt) |
SI (3) | SI3086637T1 (pt) |
TR (1) | TR201903891T4 (pt) |
TW (1) | TWI681053B (pt) |
WO (1) | WO2016089692A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3850946T (pt) | 2014-12-05 | 2024-01-02 | Regeneron Pharma | An:imais não romanos com tjm gene do grupo de diferenciação 47 romanizado |
US11284607B2 (en) * | 2015-03-24 | 2022-03-29 | The Trustees Of Columbia University In The City Of New York | Genetic modification of pigs for xenotransplantation |
KR102377189B1 (ko) | 2015-05-29 | 2022-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | C9orf72 유전자좌에서 파괴를 갖는 비-인간 동물 |
CA3003786C (en) | 2015-11-20 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
ES2908669T3 (es) | 2016-02-04 | 2022-05-03 | Regeneron Pharma | Animales no humanos que tienen un gen ANGPTL8 modificado genéticamente |
CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
WO2018031920A1 (en) | 2016-08-11 | 2018-02-15 | The Jackson Laboratory | Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals |
CN107815468B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
CN107815465B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
US11279948B2 (en) | 2016-08-31 | 2022-03-22 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric OX40 |
AU2017336100B2 (en) * | 2016-09-30 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus |
WO2018177441A1 (en) * | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
KR20200016954A (ko) * | 2017-06-12 | 2020-02-17 | 시나이 헬스 시스템 | 전신 면역억제가 불필요한 동종 이식편 내성 |
JP7262440B2 (ja) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス,インコーポレーテッド | 抗cd47抗体及びその使用 |
AU2018375796A1 (en) * | 2017-11-30 | 2020-04-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TRKB locus |
US11576984B2 (en) | 2018-03-26 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using |
KR20210031868A (ko) | 2018-07-16 | 2021-03-23 | 리제너론 파마슈티칼스 인코포레이티드 | Ditra 질환의 비인간 동물 모델 및 이의 용도 |
JP7449291B2 (ja) | 2018-12-20 | 2024-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヌクレアーゼ媒介リピート伸長 |
CN114107385A (zh) * | 2019-01-17 | 2022-03-01 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
WO2021027737A1 (en) * | 2019-08-09 | 2021-02-18 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
CN113122574A (zh) * | 2019-12-31 | 2021-07-16 | 百奥赛图(北京)医药科技股份有限公司 | 一种免疫缺陷型人源化非人动物的构建方法 |
CN112080522A (zh) * | 2020-09-15 | 2020-12-15 | 广东药康生物科技有限公司 | 一种cd47人源化小鼠模型的构建方法 |
CN112725379A (zh) * | 2021-01-27 | 2021-04-30 | 上海南方模式生物科技股份有限公司 | 人源化cd40基因改造动物模型的构建方法及应用 |
CN116064558A (zh) * | 2021-09-24 | 2023-05-05 | 百奥赛图(北京)医药科技股份有限公司 | Trop2基因人源化非人动物的构建方法及应用 |
US20240102045A1 (en) | 2022-07-19 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
WO2005044857A1 (ja) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | ヒト化抗cd47抗体 |
DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
WO2007033221A2 (en) * | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
PL2064325T3 (pl) * | 2006-09-01 | 2012-05-31 | Therapeutic Human Polyclonals Inc | Zwiększona ekspresja ludzkiej lub humanizowanej immunoglobuliny u zwierząt transgenicznych innych niż człowiek |
WO2009039244A2 (en) * | 2007-09-18 | 2009-03-26 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
CN101668387A (zh) | 2008-09-02 | 2010-03-10 | 鸿富锦精密工业(深圳)有限公司 | 印刷电路板 |
KR101742329B1 (ko) * | 2009-01-16 | 2017-05-31 | 고에끼 자이단 호우징 짓껭 도부쯔 쥬오 겡뀨쇼 | 인간 간 세포가 이식된 마우스 |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
US8354389B2 (en) | 2009-08-14 | 2013-01-15 | Regeneron Pharmaceuticals, Inc. | miRNA-regulated differentiation-dependent self-deleting cassette |
WO2011034969A1 (en) * | 2009-09-15 | 2011-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
RU2730643C2 (ru) | 2011-02-15 | 2020-08-24 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
US20140242095A1 (en) * | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
HUE048511T2 (hu) | 2011-10-28 | 2020-07-28 | Regeneron Pharma | Kiméra fõ hisztokompatibilitási komplex (MHC) II molekulákat expresszáló, genetikailag módosított egerek |
EP3262932B1 (en) | 2011-10-28 | 2019-05-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
RS53683B1 (en) | 2011-10-28 | 2015-04-30 | Regeneron Pharmaceuticals Inc. | HUMANIZOVANI IL-6 I IL-6 RECEPTOR |
EP2644027A1 (en) * | 2012-03-26 | 2013-10-02 | Institut Pasteur | Transgenic immunodefficient mouse expressing human SIRPalpha. |
US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
AU2013312359B8 (en) | 2012-09-07 | 2019-08-15 | Institute For Research In Biomedicine (Irb) | Genetically modified non-human animals and methods of use thereof |
RU2673156C2 (ru) * | 2012-11-05 | 2018-11-22 | Ридженерон Фармасьютикалз, Инк. | Генетически модифицированные не относящиеся к человеческому роду животные и способы их применения |
AU2013359167B2 (en) * | 2012-12-12 | 2018-08-23 | Arch Oncology, Inc. | Therapeutic CD47 antibodies |
CN111484999A (zh) | 2013-02-20 | 2020-08-04 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
LT3434101T (lt) | 2013-09-23 | 2023-09-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuoto signalą reguliuojančio baltymo geną |
NZ718655A (en) | 2013-10-15 | 2022-08-26 | Regeneron Pharma | Humanized il-15 animals |
CN105792646B (zh) | 2013-11-19 | 2018-03-02 | 瑞泽恩制药公司 | 具有人源化的b细胞活化因子基因的非人动物 |
MY183189A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized a proliferation-inducing ligand gene |
MX2016013241A (es) | 2014-04-08 | 2017-05-03 | Regeneron Pharma | Animales no humanos que tienen receptores fc gamma humanizados. |
NO2785538T3 (pt) | 2014-05-07 | 2018-08-04 | ||
CN113045639A (zh) | 2014-05-19 | 2021-06-29 | 再生元制药公司 | 表达人epo的经遗传修饰的非人动物 |
ES2783424T3 (es) | 2014-06-19 | 2020-09-17 | Regeneron Pharma | Animales no humanos que tienen un gen de muerte celular programada 1 humanizado |
RU2726446C2 (ru) | 2014-11-24 | 2020-07-14 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3 |
PT3850946T (pt) | 2014-12-05 | 2024-01-02 | Regeneron Pharma | An:imais não romanos com tjm gene do grupo de diferenciação 47 romanizado |
-
2015
- 2015-11-25 PT PT202150462T patent/PT3850946T/pt unknown
- 2015-11-25 LT LTEP18207075.5T patent/LT3466255T/lt unknown
- 2015-11-25 TR TR2019/03891T patent/TR201903891T4/tr unknown
- 2015-11-25 CA CA2967834A patent/CA2967834C/en active Active
- 2015-11-25 WO PCT/US2015/062614 patent/WO2016089692A1/en active Application Filing
- 2015-11-25 IL IL286403A patent/IL286403B2/en unknown
- 2015-11-25 NZ NZ731471A patent/NZ731471A/en unknown
- 2015-11-25 RS RS20210547A patent/RS61774B1/sr unknown
- 2015-11-25 CN CN201580066047.0A patent/CN107205368B/zh active Active
- 2015-11-25 PT PT182070755T patent/PT3466255T/pt unknown
- 2015-11-25 KR KR1020177013948A patent/KR102313073B1/ko active IP Right Grant
- 2015-11-25 KR KR1020237007814A patent/KR102617691B1/ko active IP Right Grant
- 2015-11-25 DK DK18207075.5T patent/DK3466255T3/da active
- 2015-11-25 RS RS20231251A patent/RS64989B1/sr unknown
- 2015-11-25 SI SI201530659T patent/SI3086637T1/sl unknown
- 2015-11-25 PL PL18207075T patent/PL3466255T3/pl unknown
- 2015-11-25 LT LTEP15813960.0T patent/LT3086637T/lt unknown
- 2015-11-25 PL PL20215046.2T patent/PL3850946T3/pl unknown
- 2015-11-25 HU HUE15813960A patent/HUE043132T2/hu unknown
- 2015-11-25 EP EP15813960.0A patent/EP3086637B1/en active Active
- 2015-11-25 JP JP2017526681A patent/JP6730277B2/ja active Active
- 2015-11-25 SG SG10202103050YA patent/SG10202103050YA/en unknown
- 2015-11-25 FI FIEP20215046.2T patent/FI3850946T3/fi active
- 2015-11-25 CN CN202011160730.XA patent/CN112342197A/zh active Pending
- 2015-11-25 SG SG11201703463WA patent/SG11201703463WA/en unknown
- 2015-11-25 DK DK15813960.0T patent/DK3086637T3/en active
- 2015-11-25 SI SI201531982T patent/SI3850946T1/sl unknown
- 2015-11-25 DK DK20215046.2T patent/DK3850946T3/da active
- 2015-11-25 ES ES18207075T patent/ES2870462T3/es active Active
- 2015-11-25 RU RU2017123357A patent/RU2728412C2/ru active
- 2015-11-25 LT LTEP20215046.2T patent/LT3850946T/lt unknown
- 2015-11-25 HU HUE18207075A patent/HUE054661T2/hu unknown
- 2015-11-25 EP EP20215046.2A patent/EP3850946B1/en active Active
- 2015-11-25 EP EP18207075.5A patent/EP3466255B1/en active Active
- 2015-11-25 BR BR112017010490A patent/BR112017010490A2/pt not_active Application Discontinuation
- 2015-11-25 SI SI201531599T patent/SI3466255T1/sl unknown
- 2015-11-25 PT PT15813960T patent/PT3086637T/pt unknown
- 2015-11-25 RS RS20190370A patent/RS58536B1/sr unknown
- 2015-11-25 EP EP23192469.7A patent/EP4296278A3/en active Pending
- 2015-11-25 AU AU2015355328A patent/AU2015355328B2/en active Active
- 2015-11-25 US US14/951,825 patent/US20160345549A1/en not_active Abandoned
- 2015-11-25 ES ES15813960T patent/ES2716735T3/es active Active
- 2015-11-25 KR KR1020217032415A patent/KR102508175B1/ko active IP Right Grant
- 2015-11-25 PL PL15813960T patent/PL3086637T3/pl unknown
- 2015-11-25 MX MX2017007293A patent/MX2017007293A/es unknown
- 2015-11-25 HR HRP20231707TT patent/HRP20231707T1/hr unknown
- 2015-12-03 TW TW104140456A patent/TWI681053B/zh active
- 2015-12-03 AR ARP150103952A patent/AR102888A1/es unknown
-
2016
- 2016-01-19 US US15/000,751 patent/US10015953B2/en active Active
- 2016-12-15 HK HK16114307A patent/HK1225912A1/zh unknown
-
2017
- 2017-04-30 IL IL252019A patent/IL252019B/en unknown
-
2018
- 2018-05-17 US US15/982,174 patent/US10939673B2/en active Active
-
2019
- 2019-03-21 CY CY20191100334T patent/CY1121547T1/el unknown
- 2019-04-02 HR HRP20190634TT patent/HRP20190634T1/hr unknown
-
2020
- 2020-07-02 JP JP2020114628A patent/JP7089554B2/ja active Active
-
2021
- 2021-01-29 US US17/161,801 patent/US11910788B2/en active Active
- 2021-04-27 HR HRP20210662TT patent/HRP20210662T1/hr unknown
- 2021-05-06 CY CY20211100382T patent/CY1124089T1/el unknown
-
2022
- 2022-06-02 AU AU2022203787A patent/AU2022203787A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017010490A2 (pt) | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. | |
BR112018010158A2 (pt) | roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga | |
BR112016029650A2 (pt) | roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor? | |
EA201991255A1 (ru) | Регулируемая транскрипция | |
AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
EP4269430A3 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
CO2019014682A2 (es) | Composiciones y métodos para enzimas de internalización | |
EP3468356A4 (en) | GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF A DISEASE | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
MX2017007636A (es) | Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado. | |
BR112016006261A2 (pt) | camundongo, célula ou tecido de camundongo isolado, e, métodos para produzir um camundongo, para enxertar células humanas em um camundongo e para avaliar a eficácia terapêutica de uma droga que alveja células humanas | |
CO2019011450A2 (es) | Expresión transgénica selectiva de tejidos | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112016015105A2 (pt) | Conjugados var2csa-droga | |
WO2014134084A3 (en) | Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy | |
BR112018001232A2 (pt) | pd-l1 que expressa células-tronco hematopoéticas e usos | |
BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
BR112015031719A2 (pt) | método para preparar aditivo de ração | |
BR112016002385A2 (pt) | animal não humano, célula, tecido ou embrião, vetor de alvejamento, constructo de vetor de alvejamento, e, métodos para produzir um animal não humano e para modificar um lócus de incrna em uma célula pluripotente | |
EP3471733A4 (en) | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING THE VIABILITY AND FUNCTIONALITY OF CELLS, TISSUES AND ORGANS | |
BR112016026245A2 (pt) | ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor? | |
WO2015181831A3 (en) | A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord | |
BR112018012070A2 (pt) | método para a produção de tecidos/ órgãos utilizando células sanguíneas | |
MX2018009513A (es) | Animales no humanos que tienen un gen angptl8 modificado genéticamente. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |